Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18452613 | 1.00 | FAAH (0.38) | FAAHCYP2C9CYP2C19CYP2D6NOD1 | |
| SCHEMBL28225556 | 0.88 | FAAH (0.39) | FAAHCYP2C9CYP2C19NOD1CYP1A2 | |
| SCHEMBL18476647 | 0.86 | FAAH (0.35) | FAAHCYP2C9CYP2C19CYP2D6ALDH1A1 | |
| SCHEMBL28748529 | 0.85 | LTA4H (0.36) | FAAHCYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL26940364 | 0.85 | LTA4H (0.36) | FAAHCYP2C9CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL18476697 | 0.84 | CYP2D6 (0.36) | CYP2C9CYP2C19CYP2D6NOD1CYP1A2 | |
| SCHEMBL29938683 | 0.83 | NOD1 (0.49) | FAAHNOD1 | |
| SCHEMBL18452721 | 0.83 | FAAH (0.34) | FAAHCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL26262639 | 0.83 | FAAH (0.34) | FAAHCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL30948764 | 0.81 | TDP1 (0.32) | FAAHCYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240797-B2 | Method of preparing a DON prodrug from L-glutamic acid | DRACEN PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | DRACEN PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2022-06-23 | — | — | US | disclosed |
| US-20220089522-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2022-03-24 | — | — | US | disclosed |
| CN-113677338-A | Method for preparing DON prodrug from L-pyroglutamic acid | 羿尊生物医药股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017023787-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023774-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023791-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023793-A2 | METHODS FOR CANCER AND IMMUNOTHERAPY USING GLUTAMINE ANALOGUES, INCLUDING DON | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089522-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID | GLUL, GLRA1, GRIN1 | FAAH 2056/4885CYP2C9 430/4885CYP2C19 294/4885 |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | FAAH 2051/4885CYP2C9 1303/4885CYP2C19 697/4885 |
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | FAAH 1065/4885CYP2C9 441/4885CYP2C19 382/4885 |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | FAAH 1526/4885CYP2C9 1740/4885CYP2C19 1250/4885 |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | GLS, GLS2, PC | FAAH 2423/4885CYP2C9 1438/4885CYP2C19 1070/4885 |
| US-11760723-B2 | Method of preparing a DON prodrug from L-pyroglutamic acid | GLS, GLS2, GLO1 | FAAH 1690/4885CYP2C9 58/4885CYP2C19 57/4885 |
| US-12240797-B2 | Method of preparing a DON prodrug from L-glutamic acid | GLUL, GLRA1, GLS | FAAH 2126/4885CYP2C9 437/4885CYP2C19 291/4885 |
| US-20220194898-A1 | METHOD OF PREPARING A DON PRODRUG FROM L-PYROGLUTAMIC ACID | GLS, GLS2, GLO1 | FAAH 1690/4885CYP2C9 58/4885CYP2C19 57/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | FAAH 3388/4885CYP2C9 316/4885CYP2C19 347/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | FAAH 3388/4885CYP2C9 316/4885CYP2C19 347/4885 |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | ADORA2A, ADORA1, ADORA2B | FAAH 1526/4885CYP2C9 1740/4885CYP2C19 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.